Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024 2024-12-12 08:30
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity 2024-11-20 22:00
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer 2024-05-23 20:42
Laekna Releases 2023 ESG Report 2024-04-29 20:30
Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024 2024-04-08 08:30
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024 2024-01-04 12:40
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results 2023-12-11 18:55
Laekna, Inc. (2105.HK) Announces Interim Results 2023 2023-08-25 08:00
1